
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is a promising company, having secured FDA clearance for their DeepView system to be used in burn and trauma centers. With a large target market of ~490k burn patients annually, Spectral AI has the potential for significant revenue growth in the future. Their partnership with BARDA and their focus on predictive medical diagnostics will likely help drive adoption of their technology.
Bears say
Spectral AI is facing a limited market opportunity with a TAM of only $3.7B, and with risks such as limited awareness of the technology, competition, and delays to regulatory and clinical timelines, the company's ability to achieve its commercialization goals and generate significant revenue may be hindered. Additionally, with a lack of significant commercial sales currently and a discounted sales analysis out to 2030, there is limited evidence to support the company's current valuation of $3 PT.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares